Nordic Life Science Platform

Noam David Stern Co-founder & Owner +86 136 1169 1358, +45 2077 5149 Address

Nordic Office: Lyngby Hovedgade 17, 2. th., 2800 Kgs. Lyngby, Denmark; China Office: Room 2003, Level 20, 989 Changle Road, Xuhui, Shanghai 200031, China



Consulting, Legal Services, IPR Protection, Life Science, Distribution & Sales

Organisation Type


Member state



English , Chinese, Danish


About Nordic Life Science Platform

The Nordic Life Science Platform (NLSP), with offices in Copenhagen and Shanghai, gives European life science companies (e.g., medtech, pharma, rehabilitation) a safer, efficient, and facilitated access to China’s rapidly expanding healthcare market by taking advantage of the preferential policies and opportunities at the Hainan Boao Lecheng International Medical Tourism Pilot Zone (HBL).

HBL is a special medical zone that aims to become a world-class international medical destination and cluster for advanced medical treatment, professional rehabilitation, medical R&D, and technological innovation in China.

HBL offers a special fast-track approval procedure that makes it easier and quicker to register, import, and sell “innovative” medical devices and medicines in need by the hospitals in HBL that are not yet registered in China but have a CE/FDA/PMDA approval.

HBL is the only place in China where it is possible to conduct Real-World Data studies of the use of medical devices and medicines imported under the fast-track approval procedure that can supplement the application for the NMPA registration and accelerate the approval process to sell in all of China.

NLSP’s mission is to match the demand for innovative medical products and solutions by the hospitals at HBL with the supply of European companies for the benefit of Chinese patients, and thereby help develop and access new business opportunities in Mainland China.

Although China is the world’s second largest market for both medical devices and medicines, many European companies hold back from starting exports or own sales in China due to lack of market knowledge and (perceived) entry barriers and therefore consider it too difficult and risky.

To lower the entry barriers, we have gathered a team of experts with many years of know-how and experience in advising and assisting foreign (medical) companies entering and operating in China.

NLSP is a one-stop service platform that delivers a Step-by-Step Market Entry Model that helps European companies to explore and enter China’s healthcare market in which HBL serves as a gateway and stepping stone to the rest of China.

We offer expert advice & supporting services such as project management, legal assistance, IPR protection, matchmaking, fast-track approval, CRO partnering for RWD study, market research, distributor search, company set-up, and product registrations.

On 12 October 2023, the NLSP, Danish Life Science Cluster, and the Lecheng Administration signed a Strategic Cooperation Agreement in Copenhagen.